Stockreport

Takeda (TAK) Receives FDA Priority Review for Rusfertide in PV Treatment [Yahoo! Finance]

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF Therapeutics announced that the US FDA accepted the NDA and granted Priority Review for rusfertide. An investigational, first-in-class hepcidin mimetic peptide, rusferti [Read more]